Official press release from Stryker or Inari Medical, or SEC filings

Stryker to Acquire Inari Medical for $4.9 Billion at $80 Per Share, Targeting VTE Treatments

Jan 6, 2025, 08:22 PM

Stryker Corp. has announced a definitive agreement to acquire Inari Medical, Inc. for $80 per share in cash, valuing the deal at approximately $4.9 billion. The acquisition aims to expand Stryker's portfolio into the high-growth peripheral vascular segment, particularly targeting venous thromboembolism (VTE) treatments. Inari's innovative product offerings, which include mechanical thrombectomy solutions for conditions like deep vein thrombosis and pulmonary embolism, are seen as complementary to Stryker's existing Neurovascular business. The transaction is expected to close by the end of the first quarter of 2025, pending customary closing conditions including regulatory approvals.